ALDX ALERT: Aldeyra Therapeutics (NASDAQ:ALDX) Investors are Reminded of Pending Securities Investigation

Core Viewpoint - Aldeyra Therapeutics, Inc. is under investigation for potential violations of federal securities laws following the failure of its lead drug candidate reproxalap in clinical trials, leading to a significant decline in stock price [1][5]. Company Overview - Aldeyra Therapeutics is a biotechnology company focused on developing therapies for immune-mediated and metabolic diseases, with reproxalap as its lead drug candidate aimed at treating dry eye disease [2]. Clinical Trial Results - The company announced success in its Phase III clinical trial for reproxalap, claiming the results were "uniquely supportive" and met FDA requirements for New Drug Application resubmission [3]. - However, the trial ultimately failed to demonstrate the drug's efficacy in treating ocular symptoms associated with dry eyes, with methodological issues identified in the trial data [4]. Stock Market Reaction - Following the FDA's Complete Response Letter on April 3, 2025, which stated that the NDA for reproxalap did not demonstrate adequate efficacy, Aldeyra's stock price plummeted nearly 75% from $5.33 per share on April 2, 2025 [5].